{"id":61844,"date":"2026-05-07T19:53:23","date_gmt":"2026-05-07T19:53:23","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/61844\/"},"modified":"2026-05-07T19:53:23","modified_gmt":"2026-05-07T19:53:23","slug":"roche-to-acquire-pathai-in-up-to-1-05-billion-deal-to-expand-digital-pathology-push-roche-holding-otc","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/61844\/","title":{"rendered":"Roche To Acquire PathAI In Up To $1.05 Billion Deal To Expand Digital Pathology Push &#8211; Roche Holding (OTC"},"content":{"rendered":"<p class=\"block core-block\">Roche <a href=\"https:\/\/www.benzinga.com\/quote\/RHHBY\" target=\"_blank\" class=\"ticker-link\" data-ticker=\"RHHBY\" data-exchange=\"OTC\" rel=\"nofollow noopener\">(OTC:<\/a><a class=\"ticker\" href=\"https:\/\/www.benzinga.com\/quote\/RHHBY\" target=\"_blank\" rel=\"nofollow noopener\">RHHBY<\/a>) said Wednesday it will acquire U.S.-based digital pathology and AI company PathAI in a deal worth up to $1.05 billion, including milestone payments. <\/p>\n<p class=\"block core-block\">The acquisition will expand Roche&#8217;s digital pathology and AI diagnostics capabilities. PathAI is set to join its diagnostics division once the deal closes later this year.<\/p>\n<p>Deal Builds On Existing Partnership<\/p>\n<p class=\"block core-block\">Under the agreement, Roche will pay $750 million upfront, with additional milestone payments of up to $300 million.<\/p>\n<p class=\"block core-block\">Roche and PathAI first partnered in 2021 and expanded their collaboration in 2024 to develop AI-enabled companion diagnostic algorithms.<\/p>\n<p class=\"block core-block\">The company said the acquisition will enhance its digital pathology portfolio by integrating PathAI&#8217;s Image Management System, AISight, with Roche&#8217;s oncology diagnostics platforms.<\/p>\n<p class=\"block core-block\">Digital pathology converts tissue samples on slides into high-resolution digital images, enabling pathologists to use AI-powered tools to support diagnostic workflows and potentially <a target=\"_blank\" href=\"https:\/\/www.benzinga.com\/general\/biotech\" rel=\"noreferrer noopener nofollow\">speed up patient results<\/a>.<\/p>\n<p>Focus On Precision Medicine And Biomarker Discovery<\/p>\n<p class=\"block core-block\">PathAI&#8217;s AI-driven tools also support clinical trials and translational research. Roche said these capabilities will complement its companion diagnostics expertise and strengthen its services for biopharma companies.<\/p>\n<p class=\"block core-block\">The combined technologies are expected to support the discovery of new biomarkers, potential drug targets, and additional diagnostic tools, helping accelerate the shift toward personalized healthcare.<\/p>\n<p class=\"block core-block\">Photo by OleksSH via Shutterstock<\/p>\n<p><a class=\"text-sm my-4\" href=\"https:\/\/www.benzinga.com\/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n<p class=\"copyright\">\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n<p class=\"block core-block\">To add Benzinga News as your preferred source on Google, <a href=\"https:\/\/google.com\/preferences\/source?q=https%3A%2F%2Fwww.benzinga.com\" rel=\"noreferrer nofollow noopener\" target=\"_blank\">click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Roche (OTC:RHHBY) said Wednesday it will acquire U.S.-based digital pathology and AI company PathAI in a deal worth&hellip;\n","protected":false},"author":2,"featured_media":58727,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[342,1016,344,914,34052,343,341,340,134,347],"class_list":{"0":"post-61844","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-ma","13":"tag-category-news","14":"tag-cms-wordpress","15":"tag-pageisbzpro-bz","16":"tag-roche","17":"tag-symbol-rhhby"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116535047390066895","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/61844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=61844"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/61844\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/58727"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=61844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=61844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=61844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}